Ab Initio is developing cancer immunotherapies, including both antibody agents and non-antibody biologics and has developed first-in-class multispecific agents that engage both the innate and adaptive immune system to attack cancer cells.
Ab Initio Biotherapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ab-initio-biotherapeutics-inc” connections=”true” suffix=””]
Ab Initio utilizes its proprietary Directed Evolution engineering technology to produce small engineering proteins, which can be potentially the next generation of anti-cancer immunotherapy drugs. Ab Initio is applying its system to the discovery of protein agents that functionally modulate G protein-coupled receptors, a superfamily of targets in a wide array of therapeutic indications including neurological, cardiovascular, endocrine, and gastrointestinal disorders, among many others.
In Dec 2016, Ab Initio entered into a research collaboration and license agreement with Pfizer for an undisclosed GPCR target, along with a strategic investment by Pfizer. Pfizer has exclusive worldwide rights to develop and commercialize any GPCR activator (_agonistÓ) antibodies against this target that may result from the collaboration. Financial details remains undisclosed.
In Mar 2015, Ab Initio won the first JLabs Quick Fire challenge, earning a coveted spot and a year of free lab space at South San Francisco J&Js new biotech incubator. Also, the studies are funded by the Ludwig Center at Stanford University.